Targeting TNFR2 to overcome acquired adaptive resistance to immune checkpoint blockade
Lena Sophie Mayer,Robert J. Orlowski,Josephine Giles,Joseph L. Benci,Gavin Ellis,Guoping Deng,John Attanasio,Zeyu Chen,Bertram Bengsch,Omar Kahn,Sasikanth Manne,Ramin S. Herati,Shin Ngiow,Sangeeth M. George,Denise L. Faustman,Gary Gilliland,Rosemarie Mick,Wei Xu,Suzanne McGettigan,Xiaowei Xu,Ravi K. Amaravadi,Giorgos C. Karakousis,Lynn M. Schuchter,Tara C. Mitchell,James L. Riley,Alexander C. Huang,Andy Minn,Vesselin Tomov,E. John Wherry
DOI: https://doi.org/10.4049/jimmunol.204.supp.165.42
2020-01-01
Abstract:Abstract Overcoming acquired adaptive immune resistance to anti-PD-1 therapy is imperative for enhancing the efficacy of immune checkpoint blockade (ICB) in solid tumors. Regulatory T cells (Tregs) play a prominent role in the suppressive tumor microenvironment (TME) and are major contributors to adaptive immune resistance. Tregs limit CD8+ T cell reinvigoration and are a promising target for combination therapy. While the clinical efficacy of anti-CTLA4 may be partially explained by restriction of Tregs, its co-administration with anti-PD1 causes significant toxicity. Thus, safer approaches to limit Treg activity are needed. To elucidate the dynamic changes in immuno-regulatory circuits within the TME during ICB, we performed deep immune profiling of peripheral blood and tumors from patients with advanced melanoma prior to (n=7) and after 1 cycle of anti-PD-1 therapy with pembrolizumab (n=9). Tregs were abundant in the TME and retained their immunosuppressive phenotype and functionality following anti-PD-1. Epigenetic, transcriptomic, and proteomic analysis of Tregs after ICB identified tumor necrosis factor receptor 2 (TNFR2) signaling as a possible driver of CD8+ T cell suppression. TNFR2 was preferentially expressed by Tregs in the TME (mean 18.03 %, SD +/− 10.13 %) relative to CD8+ T cells (mean 0.64 %, SD +/− 0.82 %) and peripheral Tregs (mean 3.16 %, SD +/− 3.21 %), suggesting it might be a safe and effective target for combination therapy. Indeed, dual blockade of TNFR2 and PD-1 led to potent CD8+ T cell expansion in two mouse tumor models, and restored sensitivity to ICB in a resistant murine model of melanoma. Our data suggest that anti-TNFR2 might synergize with current ICB by countering the development of adaptive immune resistance.